Faculty Opinions recommendation of Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

Publisher Website
Google Scholar
Abstract
Mineralocorticoid receptor antagonists (MRAs) are highly efficacious in patients with heart failure with reduced ejection fraction (HFrEF). However, the management of heart failure with preserved ejection fraction (HFpEF) represents an ongoing challenge because therapies of proven benefit in HFrEF, such as the angiotensin-receptor blocker candesartan in this trial, have repeatedly been shown to add little benefit in HFpEF (see also {1-4}). This Recommendation is of an article referenced in an F1000 Faculty Review also written by WH Wilson Tang and Takeshi Kitai.

This publication has 0 references indexed in Scilit: